论文部分内容阅读
目的观察奥扎格雷联合依达拉奉治疗老年急性进展性脑梗死的疗效及毒副反应。方法将80例急性进展性脑梗死的老年患者随机分为观察组和对照组各40例。2组患者均给予常规治疗,观察组同时给予奥扎格雷联合依达拉奉,对照组给予奥扎格雷联合胞二磷胆碱。根据卒中临床神经功能缺损评定标准(NIHSS)和日常生活能力(ADL)评分分别在治疗前后对2组患者进行评估。结果观察组有效率为87.5%均明显高于对照组的72.5%,差异有统计学意义(P<0.05),治疗前2组NIHSS评分、ADL评分差异均无统计学意义(P>0.05),治疗后2组患者NIHSS评分均降低,ADL评分均升高,且观察组变化幅度大于对照组,差异均有统计学意义(P<0.05)。2组均未见不良反应,所有患者治疗后血常规、肝肾功能、出凝血时间、心电图检查均无异常改变。结论奥扎格雷联合依达拉奉能明显改善老年急性进展性脑梗死患者神经功能缺损症状,且比较安全,值得进一步研究。
Objective To observe the efficacy and side effects of ozagral and edaravone in the treatment of senile patients with acute cerebral infarction. Methods Eighty elderly patients with acute cerebral infarction were randomly divided into observation group and control group, 40 cases each. The patients in both groups were given routine treatment. The observation group was given ozagrel combined with edaravone, while the control group was given ozagrel combined with citicoline. Two groups of patients were evaluated before and after treatment according to the criteria of NIHSS and ADL. Results The effective rate of the observation group was 87.5%, which was significantly higher than that of the control group (72.5%, P <0.05). There was no significant difference between the NIHSS and ADL scores before treatment (P> 0.05) After treatment, the NIHSS scores of both groups were decreased, the ADL scores were increased, and the changes in the observation group were greater than those in the control group (P <0.05). No adverse reactions were observed in both groups. All patients had no abnormal changes of blood routine, liver and kidney function, clotting time and electrocardiogram after treatment. Conclusion Ozagrel combined with edaravone can significantly improve the symptoms of neurological deficits in elderly patients with acute progressive cerebral infarction, and is safe and worthy of further study.